Related Experiment Video
Updated: Apr 19, 2026

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
Published on: May 4, 2017
Thiamine deficiency in cancer patients at initial admission to a palliative care unit: a single-centre
Ryota Sato1,2, Mayumi Ishida1, Nozomu Uchida3
1Psycho-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Objectives:
Thiamine deficiency (TD) has been increasingly reported among patients undergoing active cancer treatment. However, its status in end-of-life cancer patients admitted to palliative care units remains unclear. This study aimed to determine the prevalence of TD and associated factors in end-of-life cancer patients on initial admission to a palliative care unit.
Methods:
This single-centre descriptive cross-sectional study included end-of-life cancer patients admitted for the first time to a palliative care unit between 1 January 2020 and 31 December 2023. Whole blood thiamine concentrations measured on admission were analysed using high-performance liquid chromatography. The TD group was defined as <24.0 ng/mL and the thiamine normal group as 24.0-66.0 ng/mL. Patient characteristics were summarised using descriptive statistics, and factors associated with TD were examined using multivariable logistic regression, adjusting for age and clinical background variables.
Results:
TD was identified in 85 (36%) of 234 patients. Multivariable logistic regression showed that only a serum albumin level <3.0 g/dL was significantly associated with TD (adjusted OR 2.05, 95% CI 1.10 to 3.90; p=0.023). Age, body mass index, Eastern Cooperative Oncology Group performance status, a history of chemotherapy within 1 month prior to admission and gastrointestinal malignancy were not significantly associated with TD.
Conclusion:
TD was identified in 36% of end-of-life cancer patients and found to be associated with serum albumin level. In end-of-life cancer patients, particularly those with low serum albumin levels, clinicians should be mindful of the possibility of TD.
More Related Videos
04:56Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Vitamins
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Hepatic Encephalopathy
Treatment Resistant Cancers